Research map: Hepatotoxicity in the Era of Precision Medicine: Toxicological Mechanisms and Management of Immune and Cell Therapy‐Induced Liver Injury
Back to the article
Papers in this map
- The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis · Patrick M. Smith · 2013 · 5491 citations · Cited by this paper
- A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer · 2026 · Related
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up · John B.A.G. Haanen · 2017 · 2383 citations · Cited by this paper
- Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria · 2026 · Related
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment · Ethan Basch · 2017 · 2380 citations · Cited by this paper
- Exercise‐Induced Exerkines: Multi‐Nodal Suppression of the NLRP3 Inflammasome and Translational Potential · 2026 · Related
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance · Filipe Martins · 2019 · 2339 citations · Cited by this paper
- Advances in SIRT2‐Targeted Therapeutics: Structural Insights, Chemical Strategies, and Degrader Technologies · 2026 · Related
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
- AI‐Driven Multi‐Omics Integrated Applications Using Diverse Neural Networks for Breast Cancer Diagnostic Screening and Biomarker Discovery · 2026 · Related
- Immunotherapies for hepatocellular carcinoma · Josep Maria Llovet · 2021 · 1895 citations · Cited by this paper
- CART-immune-related adverse events after BCMA CAR-T therapy · 2026 · Related
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia · Joseph A. Fraietta · 2018 · 1842 citations · Cited by this paper
- FDA‐Approved Pyrimidine‐Containing Drugs: Synthesis and Clinical Application · 2025 · Related
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma · Toni K. Choueiri · 2021 · 1801 citations · Cited by this paper
- Senotherapeutics for Knee Osteoarthritis · 2026 · Related
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients · Diwakar Davar · 2021 · 1752 citations · Cited by this paper
- Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus · 2025 · Related
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma · Ann‐Lii Cheng · 2021 · 1752 citations · Cited by this paper
- Safety and efficacy of blinatumomab: a real world data · 2020 · Related
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients · Erez N. Baruch · 2020 · 1730 citations · Cited by this paper
- Human organs-on-chips for disease modelling, drug development and personalized medicine · Donald E. Ingber · 2022 · 1562 citations · Cited by this paper
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy · Antonio Di Stasi · 2011 · 1532 citations · Cited by this paper
- Immune-related adverse events of checkpoint inhibitors · Manuel Ramos‐Casals · 2020 · 1441 citations · Cited by this paper
- Mycophenolate mofetil and its mechanisms of action · ANTHONY C. ALLISON · 2000 · 1438 citations · Cited by this paper
- Bispecific antibodies: a mechanistic review of the pipeline · Aran F. Labrijn · 2019 · 1332 citations · Cited by this paper
- Multimodal biomedical AI · Julián Acosta · 2022 · 1325 citations · Cited by this paper
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade · Spencer C. Wei · 2017 · 1319 citations · Cited by this paper
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · John B.A.G. Haanen · 2022 · 1289 citations · Cited by this paper
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib · Thomas C. C. Yau · 2020 · 1278 citations · Cited by this paper
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma · Gerald P. Linette · 2013 · 1202 citations · Cited by this paper
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors · Satya Das · 2019 · 1176 citations · Cited by this paper
- Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy · Emma C. Morris · 2021 · 1120 citations · Cited by this paper
- Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis · Xinyang Song · 2019 · 1036 citations · Cited by this paper
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer · Lisa Derosa · 2018 · 908 citations · Cited by this paper
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events · Julie Renee Brahmer · 2021 · 894 citations · Cited by this paper
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer · Charles Dolladille · 2020 · 604 citations · Cited by this paper
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors · Eléonora De Martin · 2018 · 551 citations · Cited by this paper
- Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation · Mohamad Mohty · 2016 · 543 citations · Cited by this paper
Source: OpenAlex (CC0)